目的 重组人血管内皮抑制素注射液联合顺铂对肺癌恶性胸腔积液患者的治疗效果，及对核糖核苷酸还原酶M1亚基（RRM1）表达水平的影响。方法 回顾性分析2016年1月-2017年10月在青岛市城阳区人民医院接受治疗的肺癌恶性胸腔积液患者的临床资料，根据其治疗方式分为对照组和观察组，对照组给予顺铂治疗，观察组给予重组人血管内皮抑制素注射液联合顺铂治疗，1次/周，4周为1疗程，每次用药前放空胸腔积液。观察两组患者的治疗效果，比较两组患者治疗前后肿瘤标志物、胸腔积液RRM1表达水平和并发症发生率的差异。结果 观察组治疗的有效率为97.50%，明显高于对照组（82.50%）（P<0.05）。两组患者治疗前RRM1表达水平无差别；治疗后，两组RRM1表达水平均降低，同组治疗前后比较差异有统计学意义（P<0.001）；且观察组RRM1表达水平低于对照组，差异有统计学意义（P<0.001）。两组患者治疗前肿瘤标志物水平无明显差异；治疗后，两组患者的癌胚抗原（CEA）、非小细胞肺癌相关抗原（CYFRA 21-1）、癌抗原19-9（CA19-9）和癌抗原125（CA125）水平均明显降低，同组治疗前后比较差异有统计学意义（P<0.001）；且观察组患者的CEA、CYFRA21-1、CA19-9和CA125水平低于对照组，差异有统计学意义（P<0.001）。两组患者血液系统和消化道毒性，肝、肾功能损害发生率无明显差别。结论 重组人血管内皮抑制素注射液与顺铂对肺癌恶性胸腔积液患者有较好的治疗效果，可明显改善患者的肿瘤标志物和RRM1表达水平，具有良好的应用价值。

Objective To Endostar combined with cisplatin on malignant pleural effusion of lung cancer patients, and the influence on the expression of RRM1. Methods Retrospective analysis of clinical data of January 2016 to October 2017 in our hospital for treatment of malignant pleural effusion of lung cancer patients, according to the treatment methods are divided into control group and observation group, the control group was given cisplatin treatment, observation group received Endostar combined with cisplatin in the treatment. The therapeutic effects of the two groups were observed, and the difference of the tumor markers, the RRM1 expression level and the incidence of complications in the two groups before and after treatment were compared. Results In the observation group, the treatment efficiency was 97.50%, significantly higher than the control group (82.50%) (χ²=5.000, P=0.025); Before treatment, the expression level of RRM1 in the two groups of patients had no significant difference; After treatment, the observation group the expression level of RRM1 was lower than that of the control group (t=5.545, P<0.001); There was no significant difference in the level of tumor markers between the two groups before treatment. After treatment, the levels of CEA, CYFRA21-1, CA19-9 and CA125 in the observation group were lower than those in the control group (P<0.001). Two groups of patients with hematologic and gastrointestinal toxicity, liver and kidney function damage rate had no significant difference (χ²=0.082, P=0.775). Conclusion Endostar combined with cisplatin has a good therapeutic effect on lung cancer patients with malignant pleural effusion, can significantly improve the patient's tumor markers and the expression level of RRM1, has good application value.